[ad_1]
Bernardsville, N.J., March 7, 2024 (Globe Newswire) — Anima Biotech, a Tech.Bio leader in bringing AI to mRNA biology, today heads to the RNA Leaders Europe Congress on March 13th. announced their participation.th – 14th2024, Basel, Switzerland.
During the conference, Dr. Gal Gur, Vice President of Business Development at Anima, participated in two roundtable sessions, both focused on the theme “Target Selection – Lessons Learned from Small RNA Biology,” and presented his own Discuss what you learned. From research on target selection in the field of mRNA biology.The session will be held on March 14thth and 9:50 a.m. Central European Time. In addition, Gal said he will give a presentation on March 14th entitled “Introducing AI to mRNA Biology for mRNA Drug and Target Discovery.”th 11:20 a.m. Central European Time. This presentation will show how Anima’s mRNA Lightning platform uses high-content, high-throughput mRNA imaging technology to visualize the complete mRNA lifecycle from multiple disease models, and uses AI to visualize disease phenotypes. We explain how we can decipher the underlying mRNA biology of . We also discuss the platform’s applications in drug and target discovery, mRNA vaccine optimization, and RNA-based drug optimization using examples and case studies from oncology and immunology.
The RNA Leaders Europe Congress program features scientific tracks covering detailed development strategies, trends, and technologies across the long and small RNA spectrum. The conference provides an opportunity to engage key stakeholders to explore new data and case studies, evaluate the latest technologies and their potential, and build the collaborations needed to bring new discoveries to market. Offers.
About Anima Biotech
Anima Biotech is a recognized leader in small molecule mRNA medicines. Powered by strategic collaborations with Lilly, Takeda, and Abbvie, our mRNA lightning™ platform brings AI to mRNA biology. With our proprietary visualization technology, we have generated over 2 billion images of the mRNA life cycle within cells, creating disease-specific imaging neural networks that visually recognize the mRNA regulatory pathways underlying disease mechanisms. I’ve been training. Use our terascale platform to perform millions of automated biology experiments and screen for active molecules that restore images of diseased cells to a healthy phenotype. Our MOAi technology uses the mRNA biology knowledge graph, LLM, and Lightning copilot to identify its mechanism of action and molecular targets. Anima’s wholly-owned disclosed pipeline of mRNA biology modulators includes immunology (pulmonary fibrosis candidates that have progressed to preclinical stages), oncology (solid tumor lead compounds that have entered preclinical stages and lymphoma and Additional Programs for Neuroblastoma) in Neuroscience (Alzheimer’s Disease and Pain). In addition to our proprietary pipeline, we have established a strategic partnership with Pharma Inc. in the discovery of mRNA medicines, targets and vaccines. Our science was further validated with 7 patents, 16 peer-reviewed publications, and 17 scientific collaborations. For more information about Anima Biotech, please visit our website https://www.animabiotech.com and follow us on LinkedIn and X (@AnimaBiotech).
Media contact:
Andrew Mierach
Lifecy Communications
+1.646.876.5868
amielach@lifescicomms.com
[ad_2]
Source link
